Loading...
Loading...
INKT| Name | Value |
|---|---|
| Revenues | 3,769.4M |
| Cost of Revenue | 0.1M |
| Gross Profit | 1,884.7M |
| Operating Expense | 2.5M |
| Operating I/L | -2.5M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | -2.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -2.5M |
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Their lead product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy for various myeloma diseases currently in Phase 1 clinical trials. The company's revenue model is centered around the research, development, and eventual commercialization of these innovative cell therapies for the treatment of diseases.
